Market Overview:
The global cholangiocarcinoma pipeline market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of cholangiocarcinoma, rising awareness about the disease, and technological advancements in the field of cancer treatment. The global cholangiocarcinoma pipeline market is segmented on the basis of type into mono and combination therapies. On the basis of application, it is segmented into gene therapy, stem cell therapy, and other therapies. The other therapies include radiation therapy, chemotherapy, and targeted therapy. Geographically, it is segmented into North America (U.S., Canada), Latin America (Mexico), Europe (Germany), Asia Pacific (China Japan India) Middle East & Africa(South Africa).
Product Definition:
Cholangiocarcinoma Pipeline is a term used to describe the current state of research and development for a new drug or therapy. The pipeline refers to all potential therapies being researched, from early-stage studies to those that are already approved and available for use.
The importance of the cholangiocarcinoma pipeline lies in its ability to give researchers and doctors an overview of all potential therapies for this type of cancer. This can help them determine which treatments may be most effective for each individual patient, as well as helping to guide future research into this cancer.
Mono:
Mono is a single-agent medication used to treat bacterial cholangiocarcinoma. It is approved for the treatment of patients with advanced cholangiocarcinoma who are unresponsive to conventional therapy. Mono has been found to be more effective than conventional therapies in clinical trials thus far, and this trend is expected to continue during the forecast period.
Combination:
A combination of drugs is used in the treatment of cholangiocarcinoma. The most commonly used drug combinations are Sunitinib and Sipuleucel-T (SUV3903), Trastuzumab and Imatinib (Herceptin), and Panitumumab & Rituximab.
Application Insights:
The liver cancer segment dominated the global market in terms of revenue in 2017. This is due to the availability of a number of products for the treatment of liver cancer, such as sorafenib, bezlotoxumab, and cetuximab. The introduction of these drugs has led to improved survival rates for patients with hepatocellular carcinoma worldwide.
Moreover, new drug candidates are expected to enter into clinical trials soon including Nivolumab (Opdivo) and Pembrolizumab (Keytruda), which are designed to treat advanced liver cancers. These factors are anticipated to drive market growth over the forecast period in future editions.
Cholangiocarcinoma is also expected to have significant penetration in Asia Pacific owing primarilyto its increasing prevalence rate coupled with ongoing initiatives by regulatory authorities across countries such as China and India regarding early diagnosis.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased funding for research and development activities, and high incidence rate of liver cancer. The U.S.-based companies are involved in drug discovery & development programs using advanced technologies such as cell-based assays, animal models & clinical trials that are based on humanized mice or virtual reality technology for patient education & recruitment purposes.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing disposable income levels coupled with growing awareness about early diagnosis among patients suffering from liver cancers in this region. Moreover, an increase in investment by public and private entities along with favorable government policies will boost market growth during the forecast period (2018-2030). For instance, Novartis invested USD X million for a joint venture with Singapore’s sovereign wealth fund GIC Pte Ltd.
Growth Factors:
- Increasing incidence of cholangiocarcinoma
- Growing awareness about cholangiocarcinoma and its symptoms
- Rising demand for better treatment options for cholangiocarcinoma
- Availability of funding for research and development in the field of cholangiocarcinoma
- Emergence of new technologies and therapies for the treatment of cholangiocarcinoma
Scope Of The Report
Report Attributes
Report Details
Report Title
Cholangiocarcinoma Pipeline Market Research Report
By Type
Mono, Combination
By Application
Gene Therapy, Stem Cell Therapy, Gene Therapy
By Companies
Medivir, Hutchison Medipharma, Agios Pharmaceuticals, TransThera Biosciences, Senhwa Biosciences, Eisai, EMD Serono, Taiho Oncology, Sirnaomics, RedHill Biopharma, MacroGenics, Chia Tai Tianqing Pharmaceutical Group, Sirtex Medical, Delcath Systems Inc., Innovent Biologics, PCI Biotech AS, Basilea Pharmaceutica, QED Therapeutics, Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Toray Industries, Bold Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
195
Number of Tables & Figures
137
Customization Available
Yes, the report can be customized as per your need.
Global Cholangiocarcinoma Pipeline Market Report Segments:
The global Cholangiocarcinoma Pipeline market is segmented on the basis of:
Types
Mono, Combination
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gene Therapy, Stem Cell Therapy, Gene Therapy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Medivir
- Hutchison Medipharma
- Agios Pharmaceuticals
- TransThera Biosciences
- Senhwa Biosciences
- Eisai
- EMD Serono
- Taiho Oncology
- Sirnaomics
- RedHill Biopharma
- MacroGenics
- Chia Tai Tianqing Pharmaceutical Group
- Sirtex Medical
- Delcath Systems Inc.
- Innovent Biologics
- PCI Biotech AS
- Basilea Pharmaceutica
- QED Therapeutics
- Bristol-Myers Squibb
- AstraZeneca
- Eli Lilly and Company
- Toray Industries
- Bold Therapeutics
Highlights of The Cholangiocarcinoma Pipeline Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Mono
- Combination
- By Application:
- Gene Therapy
- Stem Cell Therapy
- Gene Therapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cholangiocarcinoma Pipeline Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The Cholangiocarcinoma Pipeline is a research and development program focused on the discovery and development of new treatments for cholangiocarcinoma. The pipeline includes multiple Phase 1, 2, and 3 trials targeting different aspects of the disease.
Some of the key players operating in the cholangiocarcinoma pipeline market are Medivir, Hutchison Medipharma, Agios Pharmaceuticals, TransThera Biosciences, Senhwa Biosciences, Eisai, EMD Serono, Taiho Oncology, Sirnaomics, RedHill Biopharma, MacroGenics, Chia Tai Tianqing Pharmaceutical Group, Sirtex Medical, Delcath Systems Inc., Innovent Biologics, PCI Biotech AS, Basilea Pharmaceutica, QED Therapeutics, Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Toray Industries, Bold Therapeutics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cholangiocarcinoma Pipeline Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cholangiocarcinoma Pipeline Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cholangiocarcinoma Pipeline Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cholangiocarcinoma Pipeline Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cholangiocarcinoma Pipeline Market Size & Forecast, 2018-2028
4.5.1 Cholangiocarcinoma Pipeline Market Size and Y-o-Y Growth
4.5.2 Cholangiocarcinoma Pipeline Market Absolute $ Opportunity
Chapter 5 Global Cholangiocarcinoma Pipeline Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cholangiocarcinoma Pipeline Market Size Forecast by Type
5.2.1 Mono
5.2.2 Combination
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cholangiocarcinoma Pipeline Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cholangiocarcinoma Pipeline Market Size Forecast by Applications
6.2.1 Gene Therapy
6.2.2 Stem Cell Therapy
6.2.3 Gene Therapy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cholangiocarcinoma Pipeline Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cholangiocarcinoma Pipeline Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cholangiocarcinoma Pipeline Analysis and Forecast
9.1 Introduction
9.2 North America Cholangiocarcinoma Pipeline Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cholangiocarcinoma Pipeline Market Size Forecast by Type
9.6.1 Mono
9.6.2 Combination
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cholangiocarcinoma Pipeline Market Size Forecast by Applications
9.10.1 Gene Therapy
9.10.2 Stem Cell Therapy
9.10.3 Gene Therapy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cholangiocarcinoma Pipeline Analysis and Forecast
10.1 Introduction
10.2 Europe Cholangiocarcinoma Pipeline Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cholangiocarcinoma Pipeline Market Size Forecast by Type
10.6.1 Mono
10.6.2 Combination
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cholangiocarcinoma Pipeline Market Size Forecast by Applications
10.10.1 Gene Therapy
10.10.2 Stem Cell Therapy
10.10.3 Gene Therapy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cholangiocarcinoma Pipeline Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cholangiocarcinoma Pipeline Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cholangiocarcinoma Pipeline Market Size Forecast by Type
11.6.1 Mono
11.6.2 Combination
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cholangiocarcinoma Pipeline Market Size Forecast by Applications
11.10.1 Gene Therapy
11.10.2 Stem Cell Therapy
11.10.3 Gene Therapy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cholangiocarcinoma Pipeline Analysis and Forecast
12.1 Introduction
12.2 Latin America Cholangiocarcinoma Pipeline Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cholangiocarcinoma Pipeline Market Size Forecast by Type
12.6.1 Mono
12.6.2 Combination
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cholangiocarcinoma Pipeline Market Size Forecast by Applications
12.10.1 Gene Therapy
12.10.2 Stem Cell Therapy
12.10.3 Gene Therapy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cholangiocarcinoma Pipeline Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cholangiocarcinoma Pipeline Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cholangiocarcinoma Pipeline Market Size Forecast by Type
13.6.1 Mono
13.6.2 Combination
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cholangiocarcinoma Pipeline Market Size Forecast by Applications
13.10.1 Gene Therapy
13.10.2 Stem Cell Therapy
13.10.3 Gene Therapy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cholangiocarcinoma Pipeline Market: Competitive Dashboard
14.2 Global Cholangiocarcinoma Pipeline Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Medivir
14.3.2 Hutchison Medipharma
14.3.3 Agios Pharmaceuticals
14.3.4 TransThera Biosciences
14.3.5 Senhwa Biosciences
14.3.6 Eisai
14.3.7 EMD Serono
14.3.8 Taiho Oncology
14.3.9 Sirnaomics
14.3.10 RedHill Biopharma
14.3.11 MacroGenics
14.3.12 Chia Tai Tianqing Pharmaceutical Group
14.3.13 Sirtex Medical
14.3.14 Delcath Systems Inc.
14.3.15 Innovent Biologics
14.3.16 PCI Biotech AS
14.3.17 Basilea Pharmaceutica
14.3.18 QED Therapeutics
14.3.19 Bristol-Myers Squibb
14.3.20 AstraZeneca
14.3.21 Eli Lilly and Company
14.3.22 Toray Industries
14.3.23 Bold Therapeutics
